Press release
Lung Adenocarcinoma Clinical Trials Analysis 2025: Targeted Therapies, Immunotherapies, and Novel Combinations Aim to Improve Survival and Tumor Control | DelveInsight
DelveInsight's "Lung Adenocarcinoma - Clinical Trials Analysis, 2025" describes a dynamic and fast-moving development landscape focusing on two complementary goals: (1) inhibit tumor growth and progression through targeted and immune-based therapies, and (2) improve patient survival, quality of life, and functional outcomes. Current programs include EGFR, ALK, KRAS, and MET inhibitors, immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4), and emerging bispecific antibodies and combination regimens designed to overcome resistance and enhance efficacy.Late-stage and registration-enabling efforts feature next-generation targeted drugs such as sotorasib (KRAS G12C), amivantamab (EGFR/MET bispecific), and checkpoint inhibitor combinations demonstrating meaningful improvements in progression-free survival (PFS), overall survival (OS), and response rates. Trial endpoints prioritize tumor response, PFS, OS, biomarker-based stratification, and patient-reported outcomes.
Combination strategies, adaptive trial designs, and real-world comparative studies are increasingly adopted, while regulatory momentum continues with multiple approvals and high-profile pivotal readouts reshaping the standard of care. Biomarker-guided enrollment and molecularly defined subgroups are now standard in late-phase trials to demonstrate clinical benefit and precision-targeted efficacy. Upcoming data over the next 12-24 months will determine whether emerging combinations and next-generation targeted therapies redefine first-line treatment alongside or ahead of existing standards.
Interested in learning more about the current treatment landscape and the key drivers shaping the lung adenocarcinoma pipeline? Click here: https://www.delveinsight.com/report-store/lung-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Lung Adenocarcinoma Pipeline Report
• DelveInsight's lung adenocarcinoma pipeline analysis depicts a strong space with 25+ active players working to develop 25+ pipeline drugs for lung adenocarcinoma treatment.
• The leading lung adenocarcinoma companies include BerGenBio, Innovent Biologics, Lantern Pharma, Celltrion, Pionyr Immunotherapeutics, Onconova Therapeutics, Pfizer, Chugai Pharmaceutical, Novartis Oncology, Alaunos Therapeutics, Tmunity Therapeutics, Imugene Limited, Hoffmann-La Roche, Cantargia, and others are evaluating their lead assets to improve the lung adenocarcinoma treatment landscape.
• Key lung adenocarcinoma pipeline therapies in various stages of development include Belapectin, GXHPC 1, LPCN 1148, Cellgram-LC, BIV-201, Ornithine phenylacetate, CILO, TQA 3526, Saroglitazar, LDE225, Elafibranor, OP-724, BMS 986263, CNP-104, HTD 1801, ASC42, and others.
• In May 2025, Lantern Pharma Inc. (Nasdaq: LTRN) announced that the FDA approved an amendment to its IND application, allowing the start of a Phase Ib/II clinical trial for LP-184 in a genomically defined NSCLC patient population to improve outcomes.
• In March 2025, Boan Biotechnology (06955.HK) announced that its targeted CD228 antibody-drug conjugate, BA1302, received orphan drug designation (ODD) from the FDA for squamous non-small cell lung cancer and pancreatic cancer.
• In March 2025, Johnson & Johnson announced that new data from its oncology pipeline, including overall survival results from the Phase III MARIPOSA study, will be presented at the 2025 European Lung Cancer Congress. The study evaluates RYBREVANT® (amivantamab-vmjw) plus LAZCLUZETM (lazertinib) versus osimertinib in first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R mutations.
• In February 2025, the FDA granted Fast Track designation to IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, for treating patients with unresectable, locally advanced, or metastatic squamous NSCLC that has progressed after anti-PD-(L)1 therapy and platinum-based chemotherapy.
• In January 2025, the FDA accepted and granted priority review to the BLA for Dato-DXd for adult patients with locally advanced or metastatic EGFR-mutated NSCLC who have previously received systemic therapies, including EGFR-targeted treatments. This BLA is supported by findings from the phase II TROPION-Lung05 trial, phase III TROPION-Lung01 trial, and phase I TROPION-PanTumor01 trial.
• In January 2025, the FDA granted fast-track designation to BBO-8520 for adult patients with previously treated KRAS G12C-mutated metastatic NSCLC. BBO-8520 is an investigational oral agent being evaluated in an open-label, multicenter, first-in-human phase I study for the treatment of KRAS G12C-mutated NSCLC and colorectal cancer (CRC).
• In December 2024, the FDA granted accelerated approval to BIZENGRI, the first systemic therapy for NSCLC or pancreatic adenocarcinoma (PDAC) with an NRG1 gene fusion.
Request a sample and discover the recent breakthroughs happening in the lung adenocarcinoma pipeline landscape at https://www.delveinsight.com/report-store/lung-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Lung Adenocarcinoma Overview
Lung adenocarcinoma is the most common type of non-small cell lung cancer (NSCLC), originating in the glandular cells that line the lungs and produce mucus. It typically develops in the outer regions of the lungs and is more common in non-smokers, women, and younger individuals compared to other lung cancers. Early stages may be asymptomatic, but as the disease progresses, symptoms like persistent cough, chest pain, shortness of breath, and weight loss can occur. Diagnosis is confirmed through imaging tests, biopsy, and molecular profiling to identify genetic mutations such as EGFR, ALK, or KRAS, which can guide targeted therapies. Treatment options include surgery, chemotherapy, immunotherapy, and targeted drugs, depending on the stage and genetic profile of the tumor. Early detection significantly improves prognosis, but many cases are diagnosed at an advanced stage.
Find out more about lung adenocarcinoma medication at https://www.delveinsight.com/report-store/lung-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Lung Adenocarcinoma Treatment Analysis: Drug Profile
Bemcentinib: BerGenBio
Bemcentinib is a first-in-class, oral, selective inhibitor of AXL receptor tyrosine kinase, taken once daily. AXL is a key player in cancer progression, promoting tumor growth, metastasis, survival, and resistance to therapy. It also facilitates viral entry and replication within host cells. Bemcentinib is currently in Phase II clinical trials for the treatment of lung adenocarcinoma.
Letaplimab (IBI188): Innovent Biologics
Letaplimab (IBI188) is a fully human IgG4 monoclonal antibody developed by Innovent Biologics that targets CD47, a "don't eat me" signal that inhibits macrophage-mediated phagocytosis. By blocking CD47, letaplimab enhances tumor cell clearance and activates T-cell responses. Preclinical studies confirmed its target specificity, mechanism, and antitumor efficacy. Phase 1a trials showed the drug was well tolerated up to the highest tested dose of 30 mg/kg weekly, with no dose-limiting toxicities.
Learn more about the novel and emerging lung adenocarcinoma pipeline therapies at https://www.delveinsight.com/report-store/lung-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Lung Adenocarcinoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
By Molecule Type
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Scope of the Lung Adenocarcinoma Pipeline Report
• Coverage: Global
• Key Lung Adenocarcinoma Companies: BerGenBio, Innovent Biologics, Lantern Pharma, Celltrion, Pionyr Immunotherapeutics, Onconova Therapeutics, Pfizer, Chugai Pharmaceutical, Novartis Oncology, Alaunos Therapeutics, Tmunity Therapeutics, Imugene Limited, Hoffmann-La Roche, Cantargia, and others.
• Key Lung Adenocarcinoma Pipeline Therapies: Belapectin, GXHPC 1, LPCN 1148, Cellgram-LC, BIV-201, Ornithine phenylacetate, CILO, TQA 3526, Saroglitazar, LDE225, Elafibranor, OP-724, BMS 986263, CNP-104, HTD 1801, ASC42, and others.
Dive deep into rich insights for drugs used for lung adenocarcinoma treatment, visit: https://www.delveinsight.com/report-store/lung-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Lung Adenocarcinoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Lung Adenocarcinoma Pipeline Therapeutics
6. Lung Adenocarcinoma Pipeline: Late-Stage Products (Phase III)
7. Lung Adenocarcinoma Pipeline: Mid-Stage Products (Phase II)
8. Lung Adenocarcinoma Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lung Adenocarcinoma Clinical Trials Analysis 2025: Targeted Therapies, Immunotherapies, and Novel Combinations Aim to Improve Survival and Tumor Control | DelveInsight here
News-ID: 4214096 • Views: …
More Releases from DelveInsight

Neurofibromatosis Type 1 Clinical Trials Analysis 2025: Targeted RAS-Pathway and …
The Neurofibromatosis Type 1 (NF1) clinical trial landscape in 2025 focuses on two main goals: controlling plexiform and cutaneous neurofibromas and preventing malignant peripheral nerve sheath tumors (MPNST) while improving quality of life. Current programs include RAS-MAPK pathway inhibitors, next-generation MEK inhibitors, mTOR modulators, immuno-oncology agents for MPNST, and early gene-directed therapies.
Late-stage trials primarily test oral RAS pathway inhibitors for pediatric plexiform neurofibromas, with attention to safety, functional improvement, and…

Neisseria Meningitidis Meningitis Clinical Trials Analysis 2025: Multivalent Vac …
DelveInsight's "Neisseria Meningitidis Meningitis - Clinical Trials Analysis, 2025" outlines a rapidly evolving landscape aimed at two primary goals: (1) provide broad serogroup coverage through next-generation multivalent and protein-based vaccines, and (2) improve long-term immunity and reduce disease incidence in adolescents, young adults, and high-risk populations. Ongoing programs include conjugate vaccines, adjuvanted formulations, and combination vaccines targeting meningococcal and other pediatric pathogens to optimize immunization schedules.
Late-stage and pivotal trials focus…

Essential Tremor Clinical Trials Analysis 2025: Novel Pharmacologics, Neuromodul …
DelveInsight's "Essential Tremor - Clinical Trials Analysis, 2025" highlights a dynamic development landscape focused on two complementary goals: (1) reduce tremor severity and improve motor control, and (2) enhance patient quality of life and daily functioning. Ongoing programs include small-molecule pharmacologics targeting GABAergic and calcium channel pathways, focused ultrasound neuromodulation, deep brain stimulation (DBS) refinements, and emerging gene therapy candidates aimed at long-term tremor suppression.
Late-stage and registration-enabling trials assess efficacy,…

Liver Fibrosis Clinical Trials Analysis 2025: Antifibrotic Agents, Gene Modulato …
DelveInsight's "Liver Fibrosis - Clinical Trials Analysis, 2025" outlines a rapidly evolving development landscape with two main objectives: (1) halt or reverse hepatic fibrosis progression, and (2) restore liver function and reduce risk of cirrhosis or liver-related complications. Current programs include small-molecule antifibrotics targeting TGF-β, FXR, and CCR2/CCR5 pathways, biologics aimed at inflammation and stellate cell activation, and emerging gene- and RNA-based therapies designed for durable anti-fibrotic effects.
Late-stage and pivotal…
More Releases for Lung
Lung Cancer Prevalence Driving The Lung Cancer Drugs Market: Core Growth Enabler …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Lung Cancer Drugs Industry Market Size Be by 2025?
The market for lung cancer medications has seen a swift expansion in previous years. The market size is projected to escalate from $47.94 billion in 2024 to $54.13 billion in 2025, with a compound annual growth rate…
Lung Cancer Prevalence Driving The Lung Cancer Drugs Market: An Emerging Driver …
The Lending And Payments Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Lending And Payments Market?
The lending and payments market has experienced strong growth in recent years. It is set to rise from $12,326.44 billion in 2024 to…
Transforming the Lung Cancer Drugs Market in 2025: Lung Cancer Prevalence Drivin …
What Is the Expected Size and Growth Rate of the Lung Cancer Drugs Market?
The market size for lung cancer medications has seen swift expansion in the recent past. Its growth is projected to surge from $47.94 billion in 2024 to $54.13 billion in 2025, marking a compound annual growth rate (CAGR) of 12.9%. Factors contributing to the historical period's growth include epidemiology and demographics, regulatory authorizations, healthcare system infrastructure, and…
Transforming the Lung Cancer Drugs Market in 2025: Lung Cancer Prevalence Drivin …
What Is the Expected Size and Growth Rate of the Lung Cancer Drugs Market?
The market size for lung cancer medications has seen swift expansion in the recent past. Its growth is projected to surge from $47.94 billion in 2024 to $54.13 billion in 2025, marking a compound annual growth rate (CAGR) of 12.9%. Factors contributing to the historical period's growth include epidemiology and demographics, regulatory authorizations, healthcare system infrastructure, and…
Lung Cancer Screening Market - Empowering Proactive Lung Health: The Future of C …
Newark, New Castle, USA: The "Lung Cancer Screening Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Lung Cancer Screening Market: https://www.growthplusreports.com/report/lung-cancer-screening-market/7787
This latest report researches the industry structure,…
Artificial Lung Market May Set New Growth Story | Breethe, Lung Biotechnology, M …
A new research document is added in HTF MI database of 37 pages, titled as 'Artificial Lung - Medical Devices Pipeline Assessment, 2020' with detailed analysis, Competitive landscape, forecast and strategies. The study covers important players/vendors such as ALung Technologies Inc, Breethe, Inc., Case Western Reserve University, Lung Biotechnology PBC, MC3 Inc, McGowan Institute for Regenerative , Medicine, Miromatrix Medical Inc, The Charles Stark Draper Laboratory Inc, U.S. Ann Arbor…